KROS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Keros Therapeutics Inc · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 10.07 USD
0.1% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -21.0% below the Trend Line and sits at 3.0% of its 52-week range. The latest completed week returned 0.1%, after a -10.6% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 63/100 conviction, while the latest news-sentiment score is 51/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 22 out of 100
Latest Close 10.07 USD 31 Jul 2026
1W Return 0.1% latest completed week
4W Return -10.6% short-term follow-through
12W Return -16.6% quarterly tape
Trend Breadth 55.8% 29 of 52 weeks active
Volume Ratio 0.6x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 0.1% Latest completed week; four-week move -10.6%. Indicator stack 31/40 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 63/100 conviction; expected move 30.5%. News sentiment 51/100 51 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -21.0% below the Trend Line and sits at 3.0% of its 52-week range. The latest completed week returned 0.1%, after a -10.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.6x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2012-week average 0.11

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure5/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.20Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -10.6% over four weeks, -16.6% over 12 weeks, and -29.7% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W0.1%
4W-10.6%
12W-16.6%
26W-43.8%
52W-29.7%
Active trend streak0 weeks
Active weeks in one year29
Trend breadth55.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.05Latest activity-pressure read.
Pressure change-119.7%Four-week change in activity pressure.
Leadership-36.92Latest relative-leadership reading.
RS change-8.1%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth ranks weakly; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 79% Model confidence 76%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength9/100Blend of value, momentum, and quality. Underlying universe rank 92; rank 1 is best.
Value36/100Relative valuation strength. Underlying universe rank 65; rank 1 is best.
Quality14/100Profitability and accounting quality. Underlying universe rank 87; rank 1 is best.
Momentum12/100Medium-term price momentum. Underlying universe rank 89; rank 1 is best.
Growth11/100Revenue and earnings growth. Underlying universe rank 90; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
6.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-28.2%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
96.5%
Gross profit retained from each unit of revenue.
Operating margin
-272.2%
Operating profit retained from revenue.
Free-cash-flow margin
-169.2%
Free cash flow generated from revenue.
Return on invested capital
-331.3%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-84.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-221.0%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-
Net share repurchases relative to market value.
Shareholder yield
-
Dividend yield plus net buyback yield.
Net debt / EBITDA
3.0x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

KROS shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of n/a, expected move of 30.5%, and Sharemaestro trend signal inactive.

Conviction63/100
Expected move30.5%
Put/call volume
Pressure-100
Speculation4
Volatility96
Trend agreement39
Open options detail
Insider activity16 / 4

16 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment51/100

Weighted news tone is neutral across 51 relevant articles.

11 positive · 28 neutral · 12 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
Options expected move30.5%Nearest-chain priced movement where available.
52-week drawdown-55.3%Distance below the 52-week high.
13-week volatility6.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+13.1%Week of 3 Apr.
Worst week-20.4%Week of 6 Mar.
Latest week+0.1%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains4
Flat weeks0
Modest losses8
Sharp losses8
Recent vol6.2%13-week weekly-return volatility.
Base vol7.1%52-week weekly-return volatility.
Up/down split25/27Count of positive and negative weeks in the 52-week window.
Average skew4.9% / -5.3%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape25/100

Trend, activity pressure, participation, and risk combine to a 25/100 tape read.

 Indicator analysis21/100

Latest 12-week confirmation: trend 0/12, activity pressure 5/12, relative leadership 0/12.

Activity pressure 0.20; No reversal markers Factors16/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50; Small Cap Core rank 42 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options50/100

KROS shows volatility options pressure with a 63/100 conviction score, put-call volume ratio of n/a, expected move of 30.5%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 30.5% Sentiment51/100

Weighted news tone is neutral across 51 relevant articles.

Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research Insiders16 / 4

16 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 05 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202610.07 USD0.1%12.75 USD29.62 USD-0.05-36.92768.3KOff
24 Jul 202610.06 USD-5.5%13.03 USD29.82 USD0.12-37.22851.0KOff
17 Jul 202610.64 USD-9.8%13.39 USD30.03 USD0.37-35.24997.6KOff
10 Jul 202611.80 USD4.8%13.72 USD30.23 USD0.40-31.691.4MOff
3 Jul 202611.26 USD2.5%14.04 USD30.42 USD0.24-34.161.3MOff
26 Jun 202610.99 USD3.2%14.39 USD30.60 USD0.10-35.622.5MOff
19 Jun 202610.65 USD4.9%14.60 USD30.78 USD-0.15-40.851.3MOff
12 Jun 202610.15 USD-1.5%14.83 USD30.98 USD-0.23-42.63967.2KOff
5 Jun 202610.30 USD-8.4%15.06 USD31.16 USD-0.33-40.991.1MOff
29 May 202611.25 USD0.5%15.26 USD31.37 USD-0.41-39.101.0MOff
22 May 202611.19 USD6.6%15.39 USD31.62 USD-0.59-38.252.0MOff
15 May 202610.50 USD-13.0%15.52 USD31.86 USD-0.78-41.932.2MOff
8 May 202612.07 USD5.0%15.63 USD32.11 USD-0.90-34.081.6MOff
1 May 202611.49 USD-0.2%15.75 USD32.32 USD-1.03-34.341.4MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.